Metabolize Raises $3.2M in Seed Funding Led by Astanor

Who founded Metabolize?

Metabolize was founded by Morris Laster and Gideon Meir. The company is based in San Francisco, California, with research and operations led from the region.

The company has secured an exclusive license to research originating at Stanford Medicine and has developed its scientific foundation and intellectual property portfolio around Precision Metabolite™ Technology.

"GLP-1 therapies have fundamentally changed the landscape of weight management and metabolic health, but they have not solved every challenge. We founded Metabolize to translate groundbreaking research into innovative consumer products that address these unmet needs, and ultimately help people live healthier lives," said Dr. Morris Laster, founder and CEO of Metabolize.

"Metabolic health is one of the most significant and underserved challenges facing consumers today. What stood out to us about Metabolize was the strength of the original research, the team's thoughtful approach to translating that science into consumer products, and their vision for building a new category in metabolic health. We're excited to support Dr. Laster and team as they bring that vision to life," said Christina Ulardic, Partner at Astanor.

Market and Business Growth

Metabolize has advanced its manufacturing and analytical capabilities as it prepares to commercialize its technology.

Its first product, NATLEAN, is expected to launch in January 2027. Additional products are also in development across the company's metabolic health portfolio.

What Happens Next?

Metabolize plans to bring NATLEAN to market in January 2027 while continuing to develop and validate its metabolic health products.

The company will also work on manufacturing and commercialization as it expands the applications of its Precision Metabolite™ Technology.

Read More:Texas-Based ICON Secures $200M in Series D Funding